Serplulimab (4) – Hetronifly®

Name: Frühe Nutzenbewertungen nach § 35a SGB V
Creator: Gemeinsamer Bundesausschuss

Non-small cell lung cancer, squamous cell, first-line treatment, combination with carboplatin and nab-paclitaxel

active procedures repealed resolutions


01.08.2026	21.01.2027	Serplulimab (5)	Hetronifly®	Accord Healthcare GmbH	Oncological diseases	Small-cell lung cancer, in combination with carboplatin and etoposide, first-line treatment	n.d.	active procedure
01.08.2026	21.01.2027	Serplulimab (4)	Hetronifly®	Accord Healthcare GmbH	Oncological diseases	Non-small cell lung cancer, squamous cell, first-line treatment, combination with carboplatin and nab-paclitaxel	n.d.	active procedure
01.08.2026	21.01.2027	Serplulimab (3)	Hetronifly®	Accord Healthcare GmbH	Oncological diseases	Squamous cell carcinoma of the oesophagus, PD-L1 with CPS ≥ 5, first-line treatment, in combination with fluoropyrimidine- and platinum-based chemotherapy	n.d.	active procedure
01.08.2026	21.01.2027	Serplulimab (2)	Hetronifly®	Accord Healthcare GmbH	Oncological diseases	Non-small cell lung cancer, non-squamous, EGFR-, ALK- and ROS-negative, first-line treatment, combination with carboplatin and pemetrexed	n.d.	active procedure
01.05.2025	16.10.2025	Serplulimab (1)	Hetronifly®	Accord Healthcare GmbH	Oncological diseases	Small cell lung cancer, in combination with carboplatin and etoposide, first-line treatment	3,210–7,719	100% Hint for non-quantifiable additional benefit Orphan

<< List of all resolutions